October 24, 2018 Produced and Edited by: Gregory K. Perry, PharmD, BCPS-AQID Pharmacy Clinical Manager
|
|
- Nickolas Banks
- 5 years ago
- Views:
Transcription
1 VOLUME FOUR; ISSUE 8 October 24, 2018 Produced and Edited by: Gregory K. Perry, PharmD, BCPS-AQID Pharmacy Clinical Manager
2 InPHARMation Pharmacy and Therapeutics Committee Update October 24 th, 2018 Meeting The Pharmacy and Therapeutics Committee at Hendrick Medical Center is a Medical Staff Committee that meets the fourth Wednesday of each month with five physicians and one pharmacist serving as voting members. P and T is Medical Staff Committee. The current Chair of P and T is Charles W. Fuller, M.D. Meaningful Use: eprescribing update: 44.64% Pediatric Post-Operative Pain Order Set Pedi Section and P and T Approved. The Pediatric Section and the P and T approved an order set specific to those less than 18 years of age who are post-operative. On January 1, 2018, The Joint Commission implemented new and revised pain assessment and management standards for accredited hospitals. One element of the standard was treatment and assuring non-opioid alternatives were available. HMC also has a multi-modal pain order set for adults across the continuum and orthopedic surgery patients. For more details or a copy of any of these order sets please contact Greg Perry at gperry@hendrickhealth.org or
3 Use of Codeine and Tramadol in Pediatric Patients Pedi Section and P and T approved. In response to multiple reports of serious side effects and death in children taking codeine-containing products, the FDA has issued several BLACK BOX WARNINGS against the use of codeine and tramadol in children and adolescents due to the potential for life-threatening events in children taking these medications. The purpose of this policy is to improve the safety of pediatric patients by restricting use of codeine and tramadol for children less than 18 years of age. Please see the post-operative pediatric pain order set for alternative options. This will now go to P.I. for review and approval then to MEC. Policy: A. Medications containing codeine or tramadol may not be prescribed for children < 18 years of age. These include (but are not limited to): a. Acetaminophen with codeine (Tylenol #3, Tylenol #4) b. Acetaminophen and tramadol (Ultracet) c. Butalbital, acetaminophen, caffeine, and codeine (Fioricet with Codeine) d. Codeine e. Guaifenisen and codeine (Cheratussin AC) f. Promethazine and codeine g. Promethazine, phenylephrine, and codeine (Promethazine VC/Codeine) h. Tramadol (Ultram) Daptomycin Restrictions P and T approved. Daptomycin injection is now restricted to Infectious Diseases only with the following exceptions. THIS APPLIES TO INPATIENT USE ONLY!!! NOT ED or INFUSION CENTER. 1. May be used for acute bacterial skin and skin structure infections (IE: cellulitis and erysipelas) if one of the following applies. a. Pt with acute kidney injury. b. Intolerance to vancomycin. 2. Any other use requires an Infectious Diseases consult (Dr. Canario or Kalla). a. Right sided IE. b. Left sided IE. c. Bacteremia. d. Osteomyelitis. e. Vancomycin failure (a vanco failure correlates with a daptomycin failure) daptomycin would not be recommended in cases of vanco failure. 2
4 Antimicrobial Stewardship Education by Gregory K. Perry, PharmD, BCPS-AQID Treatment of intraabdominal infections Duration of Therapy STOP-IT Trial The Study to Optimize Peritoneal Infection Therapy trial also known as the STOP-IT trial was a randomized study to compare two strategies guiding the duration of antimicrobial therapy for the management of complicated intraabdominal infection. Inclusion in the study required a complicated intraabdominal infection plus intervention to achieve adequate source control with one or more of the following: Temperature 38 C WBC 11,000/mm 3 Gastrointestinal dysfunction due to peritonitis, precluding intake of more than half their normal diet (as an indicator of an ileus) The intervention group received four days of antimicrobial therapy after source control (short course). The control group received antimicrobial therapy until two days after all of the following criteria were met: Temperature < 38 C for one entire calendar day WBC < 11,000/mm 3 Ability to consume more than half normal diet Antimicrobials were continued for a maximum of ten days The primary endpoint was a composite of surgical-site infection, recurrent intraabdominal infection requiring either surgical or percutaneous re-intervention and 30 day mortality. No difference was detected with 21.8% of the short course group meeting the endpoints vs. 22.3% in the normal course. There was no difference in the components of the composite outcomes between the groups. The median duration of therapy was 4 days in the short course group and 8 days in the control group. In conclusion please consider limiting therapy to 4 days post intervention in patients with intraabdominal infections who have undergone an adequate source control procedure as the outcome after fixed-duration antibiotic therapy (approximately 4 days) were similar to those after a longer course of antibiotics (approximately 8 days) that extended until after resolution of physiological abnormalities. Bottom line of this study: Complicated IAI can be treated with 4 days of antibiotics if adequate source control provided. Sanders JM et al. Surg Infect. (Larchmt) 2016;17: Rattan R et al. J Am Coll Surg. 2016;222: Hassinger TE et al. Surg Infect (Larchmt). 2017;18: Sawyer RG et al. N Engl J Med. 2015;372:
5 Antimicrobial Stewardship Committee (AMS) Update: Utilization Reports through July 2018 Overall utilization of antimicrobials as defined by the CDC/NHSN indicates Hendrick Medical Center is stable each month. We still are potentially using too many antibiotics. The SAAR for September 2018 was The recommendation would be if you do not need therapy directed towards Pseudomonas aeruginosa then please avoid all anti-pseudomonal antibiotics if at all possible. IF MRSA coverage is not needed please consider dc of anti-mrsa drugs sooner than later. The overall days of therapy per 1000 patient days represents a steady decline of antibiotics use over the past 5 months. If you would like to see a detailed report (Physician specific use, floor specific use, CDC specifics) please contact Greg Perry, PharmD, BCPS-AQID at gperry@hendrickhealth.org Always remember the premise of Antimicrobial Stewardship using the three R s. R = Right Drug. R = Right Dose. R = Right Duration of Therapy. 4
6 5
7 6
8 7
9 Therapeutically Speaking: by Uyen Huynh, PharmD, PGY1 Pharmacy Practice Resident HMC According to the Centers of Disease Control and Prevention (CDC), the peak months of flu activity occur from December to March. 2 Since 2010, CDC has estimated about 9.2 to 35.6 million cases of the influenza virus infection each year in the United States. 1 The concern has increased as some influenza virus strains have developed resistance to current antiviral agents such as those inhibiting M2 protein and neuraminidase. Thus new targets to attack the virus have been identified and several novel drugs have been produced and are pending for FDA approval. Among them, baloxavir marboxil has just completed its Phase II and III trials for the treatment of uncomplicated influenza in adults and adolescents. Baloxavir marboxil acts as a prodrug which hydrolyzes into baloxavir acid and selectively inhibits the cap-dependent endonuclease. This enzyme is a polymerase acidic protein which plays an important role in the initiation of viral mrna synthesis. It is administered as a single dose and can suppress the activity of both type A and B influenza virus in vitro. 4 A phase I study has shown half-life of the drug can range anywhere from 49 to 91 hours. Maximum plasma concentration is reached within 3.5 hours. The available doses are 6mg, 20 mg, 40 mg, 60 mg, and max is 80mg. Food intake can decrease plasma exposure to about 40%. 3 Similar to other anti-influenza agents, the main adverse effects of baloxavir include headache, diarrhea, and increase liver transaminases. 4 A study has shown the positive synergistic effect of baloxavir with neuraminidase inhibitors in inhibiting the replication of influenza A virus in vitro. 6 The phase II trial found statically significant results in the median time to alleviation of flu symptoms between baloxavir and placebo. Baloxavir 10 mg was 54.2 hours, 20 mg was 51 hours, 40 mg was 49.5 hours, and placebo was 77.7 hours. On treatment days 2 and 3, there was a greater reduction in the influenza virus titers in the baloxavir groups compared to placebo group. The phase III trial enrolled 12 to 64 years of age participants and initiated either baloxavir and matching placebo to oseltamivir, oseltamivir and matching placebo to baloxavir, or placebos only. The alleviation of flu symptoms was noticeably greater in patients who started the novel antiviral agent within 24 hours. The antiviral activity was seen to be superior in the baloxavir treatment group compared to placebo and oseltamivir. The magnitude and rapidity effect of the novel antiviral agents were observed to be greater compared to previous trials of systemic neuraminidase inhibitors. However, the primary clinical outcome of median time to alleviation of flu symptoms was similar in both baloxavir and oseltamivir groups. The rate of adverse events was also similar in all three groups (20.7% in baloxavir, 24.6% in placebo, and 24.8% in oseltamivir). Both phase II and III trials also detected variant viruses with I38/T/M/F substitutions that reduced baloxavir susceptibility in about 2.2% and 9.7% of recipients, respectively. 5 8
10 With the great PK/PD profile and clinical outcome for reduction of viral load, baloxavir can be used optimistically for influenza infection if the strains are resistant to M2 protein and neuraminidase inhibitors. However, susceptibility patterns to baloxavir will need to be further analyzed. According to clinicaltrials.gov, studies for baloxavir safety and efficacy in the pediatric population are planned and pending for subjects recruitment Centers for Disease Control and Prevention. (2010). Disease Burden of Influenza. Retrieved from 2. Centers for Disease Control and Prevention. (2018). Flu Season. Retrieved from 3. Koshimichi H et al. Safety, Tolerability, and Pharmacokinetics of the Novel Anti-Influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings. Clin Drug Investig Pubchem. (2018). Baloxavir marboxil. Retrieved from 5. Hayden et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. NEJM. 2018;379(10), Kitano M, Yamamoto A, Noshi T, et al. Synergistic antiviral activity of S /S , a novel inhibitor of influenza virus capdependent endonuclease, in combination with neuraminidase inhibitors in vitro. Presented at ID- Week, San Diego, CA, October 4 8, abstract. 7. ClinicalTrials.gov. (2018). Baloxavir marboxil. Retrieved from Test Your Knowledge: AB is a 56-year-old female presenting to the emergency department with a chief complaint of severe acute abdominal pain in the lower right quadrant associated with nausea and vomiting. Past medical history: type 2 diabetes mellitus, end-stage renal disease (ESRD) and breast cancer on oral chemotherapy. No recent hospitalizations. No known drug allergies. Abdominal CT reading: free air suggestive of a perforated appendix. Hospital course: taken to the operating room and underwent an appendectomy with peritoneal washout due to gross contamination and diffuse peritonitis. Assuming AB is started on the appropriate antibiotics for High Risk, Community Acquired IAI and AB is improving on postoperative day 2 of antibiotic therapy. What total duration of antibiotic therapy do you recommend? A. 2 days (i.e., therapy can be discontinued immediately) B. 4 days C. 8 days 9 D 7-10 days Test Your Knowledge Answer: Answer: B 4 days. The STOP-IT Trial was a high-yield study that assessed appropriate duration of antimicrobial therapy with appropriate source control. This was discussed in the stewardship section of this newsletter. There was no difference in the group with established source control and discontinuation of antibiotics at 4 days
11 post-op/source control vs. the control group who received antibiotics for two days post resolution of all SIRS which was a median duration of 8 days (Answer C is not correct). In the case of AB she has received 2 days of appropriate therapy so based on the STOP-IT trial she would receive two more days of IV or PO antibiotic therapy. 10
November 22, 2017 Edited by: Gregory K. Perry, PharmD, BCPS-AQID
VOLUME THREE; ISSUE 10 November 22, 2017 Edited by: Gregory K. Perry, PharmD, BCPS-AQID InPHARMation Pharmacy and Therapeutics Committee Update September 27 th, 2017 Meeting The Pharmacy and Therapeutics
More informationInPHARMation. Pharmacy and Therapeutics Committee Update September 27 th, 2017 Meeting
InPHARMation Pharmacy and Therapeutics Committee Update September 27 th, 2017 Meeting The Pharmacy and Therapeutics Committee at Hendrick Medical Center is a Medical Staff Committee that meets the fourth
More informationAnti-Influenza Agents Quantity Limit Program Summary
Anti-Influenza Agents Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2 Agent Indication Dosage & Administration Relenza Treatment of influenza in Treatment of influenza: (zanamivir) patients
More informationDecember 20, 2017 Edited by: Gregory K. Perry, PharmD, BCPS-AQID
VOLUME THREE; ISSUE 11 December 20, 2017 Edited by: Gregory K. Perry, PharmD, BCPS-AQID InPHARMation Pharmacy and Therapeutics Committee Update December 20 th, 2017 Meeting The Pharmacy and Therapeutics
More informationBrand Name: Xofluza. Generic Name: Baloxavir marboxil. Manufacturer 1 : Genetech USA, INC
Brand Name: Xofluza Generic Name: Baloxavir marboxil Manufacturer 1 : Genetech USA, INC Drug Class 2,3,4,5 : Anti-infective agent; Antiviral Agent; Endonuclease inhibitor Uses: Labeled Uses 1,2,3,4,5 :
More informationInfluenza Therapies. Considerations Prescription influenza therapies require prior authorization through pharmacy services.
Influenza Therapies Policy Number: 5.01.515 Last Review: 10/2017 Origination: 10/2002 Next Review: 10/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for influenza
More informationInfluenza Outbreaks. An Overview for Pharmacists Prescribing Antiviral Medications
Influenza Outbreaks An Overview for Pharmacists Prescribing Antiviral Medications Under the Collaborative Drug Therapy Agreement for Influenza Antiviral Medications Learning Objectives 1. Understand the
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Xofluza) Reference Number: CP.PMN.185 Effective Date: 10.30.18 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationTamiflu. Tamiflu (oseltamivir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.19 Subject: Tamiflu Page: 1 of 5 Last Review Date: March 18, 2016 Tamiflu Description Tamiflu (oseltamivir)
More informationBelow is an overview of the oral and poster presentations featuring cefiderocol and S at IDWeek 2017:
SHIONOGI TO HIGHLIGHT RESEARCH ON CEFIDEROCOL (S-649266), A SIDEROPHORE CEPHALOSPORIN, AND S-033188, A CAP-DEPENDENT ENDONUCLEASE INHIBITOR FOR TREATMENT OF INFLUENZA, AT IDWEEK 2017 OSAKA, Japan and FLORHAM
More information! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011.
Disclosure! I have no conflicts of interest related to this presentation Nina Naeger Murphy, Pharm.D., BCPS Clinical Pharmacy Specialist Infectious Diseases MetroHealth Medical Center Learning Objectives!
More informationClinical Guidance for 2009 H1N1 Influenza and Seasonal Influenza. Barbara Wallace, MD New York State Department of Health (Updated 10/8/09)
Clinical Guidance for 2009 H1N1 Influenza and Seasonal Influenza Barbara Wallace, MD New York State Department of Health (Updated 10/8/09) 1 Outline Clinical assessment Diagnostic testing Antiviral medications
More informationPrevention and Treatment of Seasonal Influenza. What to expect. Objectives 11/5/14
Prevention and Treatment of Seasonal Influenza Jason M. Pogue, PharmD, BCPS-ID Clinical Pharmacist, Infectious Diseases Sinai-Grace Hospital; Detroit Medical Center 7 November 2014 What to expect http://www.michigan.gov/mdch
More informationOral Dose of TAMIFLU for Treatment (twice daily for 5 days) of Influenza in Pediatric Patients One Year of Age and Older by
Table 1 () Oral Dose of for Treatment (twice daily for 5 days) of Influenza in Pediatric Patients One Year of Age and Older by (lbs) Dose for 5 Days Amount of for Oral Suspension to Withdraw for Each Dose
More informationUpdates to pharmacological management in the prevention of recurrent Clostridium difficile
Updates to pharmacological management in the prevention of recurrent Clostridium difficile Julia Shlensky, PharmD PGY2 Internal Medicine Resident September 12, 2017 2017 MFMER slide-1 Clinical Impact Increasing
More informationDrug Class Update with New Drug Evaluation: Influenza
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationWhat s New in Flu? An Update on Influenza Prevention and Treatment
What s New in Flu? An Update on Influenza Prevention and Treatment Kathryn M. Edwards MD Sarah H. Sell and Cornelius Vanderbilt Professor of Pediatrics Vanderbilt University Nashville, TN, USA Disclosures
More informationCOUNTY OF MORRIS DEPARTMENT OF LAW & PUBLIC SAFETY OFFICE OF HEALTH MANAGEMENT
1 COUNTY OF MORRIS DEPARTMENT OF LAW & PUBLIC SAFETY OFFICE OF HEALTH MANAGEMENT P.O. Box 900 Morristown, NJ 07963 (973) 631-5485 (973) 631-5490 Fax www.morrishealth.org 2012-2013 Influenza Season FREQUENTLY
More informationReimbursement specialists are available from 9 AM to 5 PM ET, Monday through Friday (excluding holidays) to assist you with:
Reimbursement specialists are available from 9 AM to 5 PM ET, Monday through Friday (excluding holidays) to assist you with: Disclaimer The billing and coding information contained in this document is
More informationINFLUENZA VACCINATION AND MANAGEMENT SUMMARY
INFLUENZA VACCINATION AND MANAGEMENT SUMMARY Morbidity and mortality related to influenza occur at a higher rate in people over 65 and those with underlying chronic medical conditions. Annual influenza
More informationMALDI-TOF MS: Translating Microbiology Laboratory Alphabet Soup to Optimize Antibiotic Therapy
MALDI-TOF MS: Translating Microbiology Laboratory Alphabet Soup to Optimize Antibiotic Therapy September 8, 2017 Amy Carr, PharmD PGY-2 Infectious Diseases Pharmacy Resident Seton Healthcare Family amy.carr@ascension.org
More informationJourney to Decreasing Clostridium Difficile and the Unexpected Twist. Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer
Journey to Decreasing Clostridium Difficile and the Unexpected Twist Jackie Morton, Infection Prevention Cortney Swiggart, Medication Safety Officer 4/13/2018 Objectives Discuss the organism and clinical
More informationLabeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD)
Brand Name: Dificid Generic Name: fidaxomicin Manufacturer 1,2,3,4,5 : Optimer Pharmaceuticals, Inc. Drug Class 1,2,3,4,5 : Macrolide Antibiotic Uses 1,2,3,4,5 : Labeled Uses: Treatment of Clostiridum
More informationPeramivir IV Questions and Answers for Health Care Providers
Drugs Peramivir IV Questions and Answers for Health Care Providers Q1. What action is FDA taking regarding Peramivir IV? A. As part of the federal government s response to the 2009 H1N1 public health emergency,
More informationFlu & Pneumonia Provider Toolkit
Flu & Pneumonia Provider Toolkit 2018-2019 ILQI1809.1 Molina Healthcare and Providers Work Together to Protect Members from Flu & Pneumonia Molina Healthcare of Illinois (Molina) is continuing efforts
More informationEffect of piperacillin/tazobactam restriction on usage and rates of acute renal failure
Journal of Medical Microbiology (2016), 65, 195 199 DOI 10.1099/jmm.0.000211 Effect of piperacillin/tazobactam restriction on usage and rates of acute renal failure Michael A. Lorenz, 1,2 Ryan P. Moenster
More informationD DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2
Journal of Pharmacy and Pharmacology 5 (2017) 607-615 doi: 10.17265/2328-2150/2017.09.001 D DAVID PUBLISHING Comparative Evaluation of Pharmacist-Managed Vancomycin Dosing in a Community Hospital Following
More informationWe ll be our own lifesavers. We ll get the flu vaccine.
We ll be our own lifesavers. We ll get the flu vaccine. The flu vaccine is a lifesaver for older people and those with long-term health conditions. www.immunisation.ie Flu Vaccine 2017-18 What is seasonal
More informationHuman Cases of Swine Influenza in California, Kansas, New York City, Ohio, Texas, and Mexico Key Points April 26, 2009
1 Today, CDC confirmed additional human cases of swine influenza A (H1N1) virus infection in the United States, bringing the total number of U.S. confirmed cases to 21. This includes cases in California,
More informationXP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED.
XP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED. SAFE HARBOR DISCLAIMER These slides and the accompanying oral
More informationUS FDA approves XOFLUZA (Baloxavir Marboxil) new drug to treat influenza on 24 th Oct 2018
US FDA approves XOFLUZA (Baloxavir Marboxil) new drug to treat influenza on 24 th Oct 2018 Influenza Disease Burden What is Influenza? Facts and Figures (1) A common viral infection that can be deadly,
More informationSeasonal Influenza Report
Key findings for the 2017 2018 flu season Seasonal Influenza Report 2017 2018 Influenza activity remains elevated throughout California. As of 2018 week 9 (February 25 March 3, 2018), the statewide geographic
More informationAlbiglutide: A New Treatment Option for Type II Diabetes
Volume 29, Issue 10 July 2014 Albiglutide:ANewTreatmentOption fortypeiidiabetes Bibidh Subedi, PharmD Candidate T P ITI: Albiglutide: A New Treatment Option for Type II Diabetes Zohydro : Extended-release
More informationInfluenza Prevention Update
Influenza Prevention Update Dean A. Blumberg, MD, FAAP Disclosure speakers bureau: sanofi pasteur, Merck Discussion off label use of FDA approved vaccines Influenza Prevention Update Seasonal influenza
More informationNovel H1N1 Influenza A Update. William Muth MD 2 Oct 2009
Novel H1N1 Influenza A Update William Muth MD 2 Oct 2009 Novel H1N1 Influenza A Update Epidemiology Treatment Chemoprophylaxis Vaccine Infection Prevention Novel H1N1 Influenza A International Epidemiology
More informationHEALTH ALERT SWINE INFLUENZA SITUATION UPDATE UPDATED PATIENT TESTING PRIORITIZATION INTERIM GUIDANCE ON ANTIVIRALS
HEALTH ALERT SWINE INFLUENZA SITUATION UPDATE UPDATED PATIENT TESTING PRIORITIZATION INTERIM GUIDANCE ON ANTIVIRALS DATE: May 7, 2009 TO: Physicians, Providers, and Pharmacists in San Joaquin County FROM:
More informationUPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES
DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES
More informationSTARK COUNTY INFLUENZA SNAPSHOT, WEEK 15 Week ending 18 April, With updates through 04/26/2009.
STARK COUNTY INFLUENZA SNAPSHOT, WEEK 15 Week ending 18 April, 29. With updates through 4/26/29. During week 15, countywide, state and national indicators confirmed very low markers of seasonal influenza
More information9/14/12. IDSA Pandemic and Seasonal Influenza: Principles for U.S. Action. Prediction is very difficult, especially about the future
IDSA Pandemic and Seasonal Influenza: Principles for U.S. Action Andrew T. Pavia M.D. Chair IDSA Pandemic Influenza Task Force George and Esther Gross Presidential Professor Chief Division of Pediatric
More informationSeasonal Influenza Report
Key findings for the 218 219 flu season Current Week (Week 2) Current Season Summary January 6 January 12, 219 ICU cases under 65 years: Deaths September 3, 218 January 12, 219 3 ICU cases under 65 years:
More informationSeasonal Influenza Report
Seasonal Influenza Report 218 219 CDC Disease Week 45 (November 4 November 1, 218) Updated November 13, 218 Key findings for the 218 219 flu season Current Week (Week 45) Current Season Summary November
More information2009 (Pandemic) H1N1 Influenza Virus
2009 (Pandemic) H1N1 Influenza Virus September 15, 2009 Olympia, Washington Anthony A Marfin Washington State Department of Health Goals Understand current situation & pattern of transmission of 2009 H1N1
More informationESCMID Online Lecture Library. by author
Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview
More informationInfluenza RN.ORG, S.A., RN.ORG, LLC
Influenza WWW.RN.ORG Reviewed May, 2017, Expires May, 2019 Provider Information and Specifics available on our Website Unauthorized Distribution Prohibited 2017 RN.ORG, S.A., RN.ORG, LLC PURPOSE: This
More informationSituation Update Pandemic (H1N1) August 2009
Situation Update Pandemic (H1N1) 2009 31 August 2009 Timeline pandemic (H1N1) 2009 April 12: an outbreak of influenza-like illness in Veracruz, Mexico reported to WHO April 15-17: two cases of the new
More informationSevere and Tertiary Peritonitis
Severe and Tertiary Peritonitis Addison K. May, MD FACS Professor of Surgery and Anesthesiology Division of Trauma and Surgical Critical Care Vanderbilt University Medical Center PS204: The Bad Infections:
More informationLong-Term Care Updates
Long-Term Care Updates April 2017 Bezlotoxumab to Prevent Recurrent Infection By Amy Wilson, PharmD and Zara Risoldi Cochrane, PharmD, MS, FASCP Introduction The Gram-positive bacteria is a common cause
More informationPROGRAM LOCATION & DIRECTIONS
TARGET AUDIENCE The target audience includes both community and inpatient pharmacists and pharmacy technicians. PROGRAM LOCATION & DIRECTIONS The program is being held at Carteret Health Care s Meeting
More informationAvian Influenza A (H7N9): Clinical Management. KW Choi Associate Consultant IDCTC, HA/ ICB, CHP
Avian Influenza A (H7N9): Clinical Management KW Choi Associate Consultant IDCTC, HA/ ICB, CHP Initial symptoms: nonspecific, similar to most other causes of ILI, CAP High index of suspicion and alertness
More informationClinical Outcomes of Single Tablet vs. Multi-Tablet Antiretroviral Regimens in HIV-Infected Individuals
Clinical Outcomes of Single Tablet vs. Multi-Tablet Antiretroviral Regimens in HIV-Infected Individuals Abstract #18 IRB Approved Jeannie Ong, Pharm.D., AAHIVP PGY2 HIV Pharmacotherapy Resident University
More informationHot Topic: H1N1 Flu (Swine Flu)
Hot Topic: H1N1 Flu (Swine Flu) For additional information go to: http://www.cdc.gov/ swineflu/general_info.htm Note: The information in this document is based on information from the CDC. The CDC site
More informationThe pages that follow contain information critical to protecting the health of your patients and the citizens of Colorado.
Health Alert Network Tri-County Health Department Serving Adams, Arapahoe and Douglas Counties Phone 303/220-9200 Fax 303/741-4173 www.tchd.org Follow us on Twitter @TCHDHealth and @TCHDEmergency John
More informationObjectives. Pneumonia. Pneumonia. Epidemiology. Prevalence 1/7/2012. Community-Acquired Pneumonia in infants and children
Objectives Community-Acquired in infants and children Review of Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America - 2011 Sabah Charania,
More informationDevelopment of Drugs for Bacteremia
Development of Drugs for Bacteremia Charles Knirsch, MD, MPH VP, Clinical Research Pfizer Inc 1 Bacteremia Guidance Issues EMA guidance suggests that bacteremia is not a primary diagnosis but represents
More informationClostridium difficile Infection: Diagnosis and Management
Clostridium difficile Infection: Diagnosis and Management Brian Viviano D.O. Case study 42 year old female with history of essential hypertension and COPD presents to ED complaining of 24 hours of intractable,
More informationAcute respiratory illness This is a disease that typically affects the airways in the nose and throat (the upper respiratory tract).
Influenza glossary Adapted from the Centers for Disease Control and Prevention, US https://www.cdc.gov/flu/glossary/index.htm and the World Health Organization http://www.wpro.who.int/emerging_diseases/glossary_rev_sept28.pdf?ua=1
More informationInfluenza Surveillance Report Saint Louis County Department of Public Health Week Ending 01/20/2019 Week 3
35 36 37 38 39 4 41 42 43 44 45 46 47 48 49 5 51 52 **53 1 2 3 4 5 6 7 8 9 1 11 12 13 14 15 16 17 18 19 2 21 22 23 24 25 26 27 28 29 3 31 32 33 34 Percent of Total Visits Saint Louis County Department
More informationInfluenza Surveillance Report Saint Louis County Department of Public Health Week Ending 12/30/2018 Week 52
3 36 37 38 39 4 41 42 43 44 4 46 47 48 49 1 2 **3 1 2 3 4 6 7 8 9 1 11 12 13 14 1 16 17 18 19 2 21 22 23 24 2 26 27 28 29 3 31 32 33 34 Percent of Total Visits Saint Louis County Department of Public Health
More informationWhat You Need to Know About the Flu
Wednesday, August 0, 017 BLUE P FISH E D I A T R I C S www.bluefishmd.com CYPRESS EDITION Biannual Newsletter In This Issue Find Out: Who should receive the flu vaccine? Who should NOT receive the flu
More informationMASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH WEEKLY INFLUENZA UPDATE January 4, 2019
MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH WEEKLY INFLUENZA UPDATE January 4, 2019 All data in this report are preliminary and subject to change as more information is received. Sentinel Provider Surveillance:
More informationImpact of a Pharmacist Implemented Protocol on Overall Use of Alvimopan (Entereg ) and Length of Stay in Laparoscopic Colorectal Surgeries
Journal of Pharmacy and Pharmacology 4 (2016) 521-525 doi: 10.17265/2328-2150/2016.10.001 D DAVID PUBLISHING Impact of a Pharmacist Implemented Protocol on Overall Use of Alvimopan (Entereg ) and Length
More informationUpdate I had a little bird, It s name was Enza, I opened up the window, And In Flu Enza.
I had a little bird, It s name was Enza, I opened up the window, And In Flu Enza. Update 2014 2015 Timothy R. Cassity, Ph.D. Microbiologist Southern Ohio Medical Center January 16, 2015 The opinions expressed
More informationSeasonal Influenza Report
Key findings for the 2017 2018 flu season October 1 st, 2017 (CDC Disease Week 40) marked the beginning of the 2017 2018 influenza season. Influenza activity is increasing in California. As of November
More informationHow many students at St. Francis Preparatory School in New York City have become ill or been confirmed with swine flu?
Swine Flu Call Center Script SWINE FLU QUESTIONS What is swine flu? Swine Influenza, also called swine flu, is a respiratory disease of pigs caused by type A influenza viruses. Outbreaks of swine flu happen
More informationAntimicrobial resistance Fact sheet N 194 Updated April 2014
Antimicrobial resistance Fact sheet N 194 Updated April 2014 Key facts Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by
More informationEvelyn A. Kluka, MD FAAP November 30, 2011
Evelyn A. Kluka, MD FAAP November 30, 2011 > 80% of children will suffer from at least one episode of AOM by 3 years of age 40% will have > 6 recurrences by age 7 years Most common diagnosis for which
More informationSeasonal Influenza Report
Key findings for the 2017 2018 flu season Seasonal Influenza Report 2017 2018 Influenza activity is widely circulating in California. As of week 52 (December 24 30, 2017), the statewide geographic distribution
More informationTHIS ACTIVITY HAS EXPIRED. CME CREDIT IS NO LONGER AVAILABLE
THIS ACTIVITY HAS EXPIRED. CME CREDIT IS NO LONGER AVAILABLE The following content is provided for informational purposes only. PREVENTION AND CONTROL OF INFLUENZA Lisa McHugh, MPH Influenza can be a serious
More informationRevised Recommendations for the Use of Influenza Antiviral Drugs
QUESTIONS & ANSWERS Revised Recommendations for the Use of Influenza Antiviral Drugs Background On September 8, 2009 CDC updated its recommendations for the use of influenza antiviral medicines to provide
More informationInfluenza Update for Iowa Long-Term Care Facilities. Iowa Department of Public Health Center for Acute Disease Epidemiology
Influenza Update for Iowa Long-Term Care Facilities Iowa Department of Public Health Center for Acute Disease Epidemiology Webinar Information All participants will be muted during the presentation. Questions
More informationClinical Development Challenges: Trial Designs and Endpoints
Clinical Development Challenges: Trial Designs and Endpoints Menno de Jong Department of Medical Microbiology Academic Medical Center, University of Amsterdam ISIRV - Options IX for the Control of Influenza
More informationLearning Objectives. A Critical Analysis of Recent Fidaxomicin & Nesiritide Trials. Fidaxomicin vs. Vancomycin. Outline 1/3/2012
Learning Objectives A Critical Analysis of Recent Fidaxomicin & Nesiritide Trials Amy E. Lodolce, PharmD, BCPS Assistant Director, Drug Information Group UIC College of Pharmacy Describe the methods and
More informationInfluenza : What is going on? How can Community Health Centers help their patients?
Influenza 2008-2009: What is going on? How can Community Health Centers help their patients? Beth Nivin Bureau of Communicable Diseases New York City Dept. of Health and Mental Hygiene By the end of this
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationMethicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods
Methicillin-Resistant Staphylococcus aureus (MRSA) Surveillance Report 2008 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services
More informationFACT SHEET. H1N1 Influenza phone
www.cookcountypublichealth.org 708-492-2000 phone H1N1 Influenza FACT SHEET What is novel H1N1? Novel H1N1 (referred to as swine flu early on) is a new influenza virus causing illness in people. This new
More informationHealth technology The use of oseltamivir for the treatment of influenza in otherwise healthy children.
Effect of influenza treatment with oseltamivir on health outcome and costs in otherwise healthy children Reisinger K, Greene G, Aultman R, Sander B, Gyldmark M Record Status This is a critical abstract
More informationPHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 5/18/17 SECTION: DRUGS LAST REVIEW DATE: 5/17/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
ALLZITAL (butalbital and acetaminophen) 25 mg/325 mg oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationWhat is Influenza? Patricia Daly MD, FRCPC Medical Health Officer and Medical Director of Communicable Disease Control
Vancouver Coastal Health & The Vancouver Coastal Health Research Institute presents: On Call with VGH Experts Lecture Series The Flu and You What is Influenza? Patricia Daly MD, FRCPC Medical Health Officer
More informationGazyva. Gazyva (obinutuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: March 16, 2018 Gazyva Description Gazyva (obinutuzumab)
More informationNeutropenic Fever. CID 2011; 52 (4):e56-e93
Neutropenic Fever www.idsociety.org CID 2011; 52 (4):e56-e93 Definitions Fever: Single oral temperature of 101 F (38.3 C) Temperature 100.4 F (38.0 C) over 1 hour Neutropenia: ANC < 500 cells/mm 3 Expected
More informationTexas Influenza Summary Report, Season (September 28, 2008 April 11, 2009)
Texas Influenza Summary Report, 2008 2009 Season (September 28, 2008 April 11, 2009) Background Influenza and influenza-like illnesses (ILI) were last reportable by law in any county in Texas in 1993 (1).
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationFamily Medicine Clinical Pharmacy Forum Vol. 3, Issue 1 (January/February 2007)
1 Family Medicine Clinical Pharmacy Forum Vol. 3, Issue 1 (January/February 2007) Family Medicine Clinical Pharmacy Forum is a brief bi-monthly publication from the Family Medicine clinical pharmacists
More informationPharmacotherapy Handbook
Pharmacotherapy Handbook Eighth Edition Barbara G. Wells, PharmD, HP, FCCP, BCPP Dean and Professor Executive Director, Research Institute of Pharmaceutical Sciences School of Pharmacy, The University
More informationAdult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016
Adult Inpatient Antibiogram Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates January to December 2016 Department of Pathology Camille Hamula, PhD Director, Clinical Microbiology
More informationnumber Done by Corrected by Doctor
number 34 Done by حسام ابو عوض Corrected by Waseem Alhaj Doctor مالك الزحلف Antiviral Chemotherapy (chemotherapy is another way of saying drugs بنحب نتفلسف وهيك.(بس When dealing with viruses we are entering
More informationH1N1 Influenza. Situation Update
TABLE OF CONTENTS H1N1 Influenza 1-2 UIMC Executive Summary of the Management of Novel Influenza A (H1N1) Virus 3-4 Emergency Use of Peramivir Approved 5-6 P&T Committee Formulary Action 6 H1N1 Influenza
More informationClostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure
Clostridium DifficileInfection & Readmissions: An ounce of prevention is worth a pound of cure Brian S. Zuckerbraun, MD, FACS Henry T. Bahnson Professor of Surgery University of Pittsburgh Chief, Trauma
More information4/26/2016. Disclosure. Institution. Objectives. Background. Background
Pharmacist-led patient education: the impact of managing chemotherapy-induced nausea and vomiting (CINV) in ambulatory oncology patients Kristyn Gutowski, PharmD, RPh PGY1 Pharmacy Resident St. Vincent
More informationInfant and Pediatric Influenza. Mike Czervinske RRT-NPS University of Kansas Medical Center
Infant and Pediatric Influenza Mike Czervinske RRT-NPS University of Kansas Medical Center Influenza Infants and Influenza Acute infection of the respiratory tract Nose Throat Possibly lungs Pathophysiology
More informationGuidelines for clinical management of severe influenza infection. Aeron Hurt
Guidelines for clinical management of severe influenza infection Aeron Hurt Current WHO guidelines WHO guidance documents for the clinical management of influenza virus infection were published in 2007
More informationOpen Forum Infectious Diseases MAJOR ARTICLE
Open Forum Infectious Diseases MAJOR ARTICLE Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting:
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 26 September 2007 RELENZA 5mg/dose, inhalation powder, in single-dose containers 20 single-dose containers with an
More informationInfluenza-Associated Pediatric Mortality rev Jan 2018
rev Jan 2018 Infectious Agent Influenza A, B or C virus BASIC EPIDEMIOLOGY Transmission Transmission occurs via droplet spread. After a person infected with influenza coughs, sneezes, or talks, influenza
More information10/29/2014. Influenza Surveillance and Reporting. Outline
Influenza Surveillance and Reporting Stefanie DeVita, RN, MPH Influenza Epidemiologist MDCH Division of Immunization Michigan Society of Health-System Pharmacists Annual Meeting November 7, 2014 Outline
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information